Pseudoirreversible inhibition elicits persistent efficacy of a sphingosine 1-phosphate receptor 1 antagonist

Nat Commun. 2024 Jul 19;15(1):5743. doi: 10.1038/s41467-024-49893-8.

Abstract

Sphingosine 1-phosphate receptor 1 (S1PR1), a G protein-coupled receptor, is required for lymphocyte trafficking, and is a promising therapeutic target in inflammatory diseases. Here, we synthesize a competitive S1PR1 antagonist, KSI-6666, that effectively suppresses pathogenic inflammation. Metadynamics simulations suggest that the interaction of KSI-6666 with a methionine residue Met124 in the ligand-binding pocket of S1PR1 may inhibit the dissociation of KSI-6666 from S1PR1. Consistently, in vitro functional and mutational analyses reveal that KSI-6666 causes pseudoirreversible inhibition of S1PR1, dependent on the Met124 of the protein and substituents on the distal benzene ring of KSI-6666. Moreover, in vivo study suggests that this pseudoirreversible inhibition is responsible for the persistent activity of KSI-6666.

MeSH terms

  • Animals
  • HEK293 Cells
  • Humans
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Sphingosine-1-Phosphate Receptors* / antagonists & inhibitors
  • Sphingosine-1-Phosphate Receptors* / metabolism

Substances

  • Sphingosine-1-Phosphate Receptors
  • S1PR1 protein, human